Document is current
Any future updates will be listed below
-
Authors
Lawrence-Paul, Matthew R.
Pan, Tien-chi
Pant, Dhruv K.
Shih, Natalie N. C.
Chen, Yan
Belka, George K.
Feldman, Michael
DeMichele, Angela
Chodosh, Lewis A. https://orcid.org/0000-0003-1027-8674
-
Funding
Funding for this research was provided by:
National Cancer Institute
Breast Cancer Research Foundation
Rhoda Polly Danziger and Michael Danziger
Congressionally Directed Medical Research Programs
- License Information
-
More Information
Article History
Received: 29 March 2023
Accepted: 22 January 2024
First Online: 6 February 2024
Declarations
:
: Tumors were obtained from patients who provided informed consent to a research tumor biopsy as part of the METAMORPH Study (“Metastatic Markers of the Recurrent Phenotype”) and were ascertained from the clinical practices of the Rena Rowan Breast Center at the University of Pennsylvania, Philadelphia, Pennsylvania, USA (IRB 1, Protocol 818874). This study conformed to the principles of the Helsinki Declaration.
: Not applicable.
: LAC has served as an expert consultant to Teva Pharmaceuticals, Eisai, Sanofi, Eli Lilly, Whittaker, Clark and Daniels, Wyeth, Imerys, Colgate, Becton Dickinson, Sterigenics, and the U.S. Department of Justice in litigation. AD serves as principal investigator for clinical trials for which the University of Pennsylvania receives research funding from Novartis, Pfizer, Genentech, Calithera, and Menarini. The remaining authors declare that they have no competing interests.
